Long term growth hormone (GH)-releasing hormone and biosynthetic GH therapy in GH-deficient children: comparison of therapeutic effectiveness.
Twenty-five GH-deficient children were treated with GHRH (1-44), once daily sc for 6-24 months. At the 6th month of therapy, 40% of our patients showed a catch-up growth (responders), while the remaining 60% did not (nonresponders). No differences in auxological and biological variables at inclusion were found between the two groups. However, integrated GH secretion elicited by iv GHRH at inclusion was significantly (p less than 0.025) higher in responders than in non responders. During GHRH therapy, no significant increase in IGF 1/SmC was found in both groups. In all patients treatment was discontinued after 6-24 months, when its effect on growth rate failed. After a wash-out period of at least 6 months, patients were submitted to biosynthetic GH therapy. After 6 months of GH treatment a significant catch-up growth was found in both responder and non-responder children. Although the majority of GH-deficient children have hypothalamic rather than pituitary dysfunction, GHRH therapy is found to be less effective than GH treatment. Other methods of GHRH administration are worth investigating.
Bozzola
M
M
Clinica Pediatrica, Università di Pavia, Italy.
Biscaldi
I
I
Cisternino
M
M
Severi
F
F
Balsamo
A
A
Cacciari
E
E
Pellini
C
C
Chiumello
G
G
Spadoni
G L
GL
Boscherini
B
B
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000473:pathology; D013006:Growth Hormone / Q000008:administration & dosage / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D010906:Pituitary Hormone-Releasing Hormones / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013810:Therapeutic Equivalency
D010906:Pituitary Hormone-Releasing Hormones; D013006:Growth Hormone